Lubka T Roumenina

List of Publications by Year
in descending order

118	9,366	61945 43	40954 93
papers	citations	h-index	g-index

131	131	131	8749
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Coagulome and the tumor microenvironment: an actionable interplay. Trends in Cancer, 2022, 8, 369-383.	3.8	44
2	C1q+ macrophages: passengers or drivers of cancer progression. Trends in Cancer, 2022, 8, 517-526.	3.8	51
3	A role for complement blockade in kidney transplantation. , 2022, , .		2
4	Ex Vivo Test for Measuring Complement Attack on Endothelial Cells: From Research to Bedside. Frontiers in Immunology, 2022, 13, 860689.	2.2	9
5	Heme induces human and mouse platelet activation through C-type-lectin-like receptor-2. Haematologica, 2021, 106, 626-629.	1.7	44
6	Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis. Kidney International, 2021, 99, 581-597.	2.6	48
7	Plasma C3d levels as a diagnostic marker for complete complement factor I deficiency. Journal of Allergy and Clinical Immunology, 2021, 147, 749-753.e2.	1.5	6
8	The receptor for advanced glycation end products is a sensor for cellâ€free heme. FEBS Journal, 2021, 288, 3448-3464.	2.2	16
9	The Benefits of Complement Measurements for the Clinical Practice. Methods in Molecular Biology, 2021, 2227, 1-20.	0.4	2
10	Detection of Anti-C3b Autoantibodies by ELISA. Methods in Molecular Biology, 2021, 2227, 133-139.	0.4	1
11	Complement Detection in Human Tumors by Immunohistochemistry and Immunofluorescence. Methods in Molecular Biology, 2021, 2227, 191-203.	0.4	5
12	Complement C3 Deposition on Endothelial Cells Revealed by Flow Cytometry. Methods in Molecular Biology, 2021, 2227, 97-105.	0.4	1
13	Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases. International Journal of Molecular Sciences, 2021, 22, 2009.	1.8	19
14	Ex Vivo Complement Activation on Endothelial Cells: Research and Translational Value. Trends in Molecular Medicine, 2021, 27, 418-421.	3.5	1
15	Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer Immunology Research, 2021, 9, 909-925.	1.6	40
16	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunology Research, 2021, 9, 891-908.	1.6	43
17	Heme: driver of erythrocyte elimination. Blood, 2021, 138, 1092-1094.	0.6	3
18	Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy. Frontiers in Immunology, 2021, 12, 680567.	2.2	24

#	Article	IF	Citations
19	Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis. Frontiers in Immunology, 2021, 12, 690821.	2.2	13
20	Chronic histiocytic intervillositis: manifestation of placental alloantibody-mediated rejection. American Journal of Obstetrics and Gynecology, 2021, 225, 662.e1-662.e11.	0.7	13
21	Complement factor H: a guardian within?. Kidney International, 2021, 100, 747-749.	2.6	2
22	Terminal complement without C5 convertase?. Blood, 2021, 137, 431-432.	0.6	2
23	B cells and cancer: To B or not to B?. Journal of Experimental Medicine, 2021, 218, .	4.2	91
24	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. Genome Medicine, 2020, 12, 86.	3.6	63
25	Hemopexin as an Inhibitor of Hemolysis-Induced Complement Activation. Frontiers in Immunology, 2020, 11, 1684.	2.2	24
26	Complement System: Promoter or Suppressor of Cancer Progression?. Antibodies, 2020, 9, 57.	1.2	58
27	B cells and complement at the forefront of chemotherapy. Nature Reviews Clinical Oncology, 2020, 17, 393-394.	12.5	9
28	Anti-Factor B Antibodies and Acute Postinfectious GN in Children. Journal of the American Society of Nephrology: JASN, 2020, 31, 829-840.	3.0	50
29	Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis. Frontiers in Immunology, 2020, 11, 1772.	2.2	8
30	Analysis of protein missense alterations by combining sequenceâ€•and structureâ€‘based methods. Molecular Genetics & Genomic Medicine, 2020, 8, e1166.	0.6	25
31	Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. American Journal of Hematology, 2020, 95, 456-464.	2.0	46
32	Clinical and functional consequences of antiâ€properdin autoantibodies in patients with lupus nephritis. Clinical and Experimental Immunology, 2020, 201, 135-144.	1.1	4
33	Context-dependent roles of complement in cancer. Nature Reviews Cancer, 2019, 19, 698-715.	12.8	217
34	The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction. Transfusion Medicine Reviews, 2019, 33, 225-230.	0.9	16
35	Glomerulonephritis With Isolated C3 Deposits as a Manifestation of Subtotal Factor I Deficiency. Kidney International Reports, 2019, 4, 1354-1358.	0.4	3
36	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. Cancer Immunology Research, 2019, 7, 1091-1105.	1.6	153

#	Article	IF	Citations
37	Anti-inflammatory activity of intravenous immunoglobulin through scavenging of heme. Molecular Immunology, 2019, 111, 205-208.	1.0	8
38	P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6280-6285.	3.3	90
39	Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions. Transfusion Clinique Et Biologique, 2019, 26, 116-124.	0.2	32
40	Autoantibodies Against C3bâ€"Functional Consequences and Disease Relevance. Frontiers in Immunology, 2019, 10, 64.	2.2	22
41	Hemolysis Derived Products Toxicity and Endothelium: Model of the Second Hit. Toxins, 2019, 11, 660.	1.5	55
42	Hemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H. Pediatric Nephrology, 2019, 34, 533-537.	0.9	4
43	Endothelium structure and function in kidney health and disease. Nature Reviews Nephrology, 2019, 15, 87-108.	4.1	292
44	Detection of Autoantibodies to Complement Components by Surface Plasmon Resonance-Based Technology. Methods in Molecular Biology, 2019, 1901, 271-280.	0.4	4
45	Abstract 2334: Intratumoral classical complement pathway promotes tumor growth in renal cancer. , 2019, , .		0
46	Abstract 2334: Intratumoral classical complement pathway promotes tumor growth in renal cancer. , 2019, , .		0
47	Site-specific N-glycosylation analysis of soluble FcÎ³ receptor IIIb in human serum. Scientific Reports, 2018, 8, 2719.	1.6	21
48	Complement C3 is a novel modulator of the anti-factor VIII immune response. Haematologica, 2018, 103, 351-360.	1.7	17
49	FP076ATYPICAL HEMOLYTIC UREMIC SYNDROME - WHY THE KIDNEY?. Nephrology Dialysis Transplantation, 2018, 33, i74-i74.	0.4	0
50	A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein. Frontiers in Immunology, 2018, 9, 2822.	2.2	7
51	Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1. Frontiers in Immunology, 2018, 9, 3008.	2.2	36
52	Intratumoral classical complement pathway promotes tumor growth in renal cancer. Molecular Immunology, 2018, 102, 205.	1.0	0
53	Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. Frontiers in Immunology, 2018, 9, 2260.	2.2	42
54	Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis. Frontiers in Immunology, 2018, 9, 179.	2.2	41

#	Article	IF	Citations
55	Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight, 2018, 3, .	2.3	135
56	LBA29 COMPLEMENT ACTIVATION ORCHESTRATED BY CANCER CELLS AND C1Q-PRODUCING TUMOR ASSOCIATED MACROPHAGES HAS A DELETERIOUS IMPACT ON PATIENTâ€™S PROGNOSIS IN CLEAR CELL RENAL CELL CANCER.. Journal of Urology, 2018, 199, .	0.2	0
57	ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A Â«KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMESÂ» (KDIGO) CONTROVERSIES CONFERENCE. Nephrology (Saint-Petersburg), 2018, 22, 18-39.	0.1	0
58	Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2017, 28, 1603-1613.	3.0	83
59	Functional and structural insight into properdin control of complement alternative pathway amplification. EMBO Journal, 2017, 36, 1084-1099.	3.5	69
60	Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival. Inflammation, 2017, 40, 117-122.	1.7	9
61	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney International, 2017, 92, 1232-1241.	2.6	93
62	A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. Kidney International, 2017, 92, 876-887.	2.6	35
63	Intravascular hemolysis induces complement system activation. Molecular Immunology, 2017, 89, 164.	1.0	0
64	Atypical hemolytic uremic syndrome â€“ Why the kidney?. Molecular Immunology, 2017, 89, 172-173.	1.0	0
65	Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling. Journal of Immunology, 2016, 197, 3669-3679.	0.4	25
66	Endothelial cells: source, barrier, and target of defensive mediators. Immunological Reviews, 2016, 274, 307-329.	2.8	88
67	Heme: Modulator of Plasma Systems in Hemolytic Diseases. Trends in Molecular Medicine, 2016, 22, 200-213.	3.5	126
68	A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. Journal of the American Society of Nephrology: JASN, 2016, 27, 1665-1677.	3.0	39
69	Loss of DGKÎµ induces endothelial cell activation and death independently of complement activation. Blood, 2015, 125, 1038-1046.	0.6	69
70	Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood, 2015, 125, 2359-2369.	0.6	112
71	C3dg-CR3 interaction in erythrophagocytosis. Blood, 2015, 126, 828-829.	0.6	1
72	Complement System Part II: Role in Immunity. Frontiers in Immunology, 2015, 6, 257.	2.2	762

#	Article	IF	Citations
73	Complement System Part I Ã¢â‚¬â€œ Molecular Mechanisms of Activation and Regulation. Frontiers in Immunology, 2015, 6, 262.	2.2	1,161
74	Intravenous Immunoglobulin with Enhanced Polyspecificity Improves Survival in Experimental Sepsis and Aseptic Systemic Inflammatory Response Syndromes. Molecular Medicine, 2015, 21, 1002-1010.	1.9	24
75	Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Antiâ€“Factor H IgAÎ» Antibody. American Journal of Kidney Diseases, 2015, 66, 331-336.	2.1	21
76	Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis. Journal of Biological Chemistry, 2015, 290, 25343-25355.	1.6	44
77	Mechanism and Functional Implications of the Heme-Induced Binding Promiscuity of IgE. Biochemistry, 2015, 54, 2061-2072.	1.2	13
78	Antiâ€“Factor H Autoantibodies in C3 Glomerulopathies and in Atypical Hemolytic Uremic Syndrome: One Target, Two Diseases. Journal of Immunology, 2015, 194, 5129-5138.	0.4	99
79	Complement Factor B Mutations in Atypical Hemolytic Uremic Syndromeâ€”Disease-Relevant or Benign?. Journal of the American Society of Nephrology: JASN, 2014, 25, 2053-2065.	3.0	107
80	The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood, 2014, 123, 121-125.	0.6	63
81	Functional Evaluation of Factor H genetic and Acquired Abnormalities: Application for Atypical Hemolytic Uremic Syndrome (aHUS). Methods in Molecular Biology, 2014, 1100, 237-247.	0.4	15
82	Anti-Factor H Autoantibodies Assay. Methods in Molecular Biology, 2014, 1100, 249-256.	0.4	12
83	Antibody Polyreactivity in Health and Disease: Statu Variabilis. Journal of Immunology, 2013, 191, 993-999.	0.4	100
84	Complement factor H related proteins (CFHRs). Molecular Immunology, 2013, 56, 170-180.	1.0	214
85	An Engineered Construct Combining Complement Regulatory and Surface-Recognition Domains Represents a Minimal-Size Functional Factor H. Journal of Immunology, 2013, 191, 912-921.	0.4	70
86	Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. Nephrology Dialysis Transplantation, 2013, 28, 2899-2907.	0.4	25
87	Physiological and therapeutic complement regulators in kidney transplantation. Current Opinion in Organ Transplantation, 2013, 18, 421-429.	0.8	11
88	Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood, 2013, 122, 282-292.	0.6	207
89	Overall Neutralization of Complement Factor H by Autoantibodies in the Acute Phase of the Autoimmune Form of Atypical Hemolytic Uremic Syndrome. Journal of Immunology, 2012, 189, 3528-3537.	0.4	96
90	Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nature Reviews Nephrology, 2012, 8, 643-657.	4.1	448

#	Article	IF	Citations
91	Exploration du complÃ©ment : actualitÃ©s 2012. Revue Francophone Des Laboratoires, 2012, 2012, 31-37.	0.0	2
92	Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus antiâ€C1q antibodies by a specific peptideâ€based enzymeâ€linked immunosorbent assay. Arthritis and Rheumatism, 2012, 64, 3706-3714.	6.7	37
93	A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood, 2012, 119, 4182-4191.	0.6	128
94	Genetics of hemolytic uremic syndromes. Presse Medicale, 2012, 41, e105-e114.	0.8	28
95	Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney International, 2012, 82, 454-464.	2.6	454
96	Renal Transplantation Under Prophylactic Eculizumab in Atypical Hemolytic Uremic Syndrome With CFH/CFHR1 Hybrid Protein. American Journal of Transplantation, 2012, 12, 1938-1944.	2.6	70
97	Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood, 2011, 117, 1340-1349.	0.6	188
98	Alternative complement pathway assessment in patients with atypical HUS. Journal of Immunological Methods, 2011, 365, 8-26.	0.6	140
99	Functional Complement C1q Abnormality Leads to Impaired Immune Complexes and Apoptotic Cell Clearance. Journal of Immunology, 2011, 187, 4369-4373.	0.4	58
100	1st EFIS-EJI Intensive Course in Clinical Immunology: Towards a new era in Immunology. European Journal of Immunology, 2011, 41, 268-269.	1.6	2
101	Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort. PLoS Medicine, 2011, 8, e1001013.	3.9	240
102	Heme Interacts with C1q and Inhibits the Classical Complement Pathway. Journal of Biological Chemistry, 2011, 286, 16459-16469.	1.6	56
103	A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope. Journal of Thrombosis and Haemostasis, 2010, 8, 1524-1531.	1.9	13
104	Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations. Journal of the American Society of Nephrology: JASN, 2010, 21, 859-867.	3.0	383
105	Atypical Hemolytic Uremic Syndrome Associated with Mutations in Complement Regulator Genes. Seminars in Thrombosis and Hemostasis, 2010, 36, 641-652.	1.5	41
106	Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. Molecular Immunology, 2009, 47, 290-297.	1.0	6
107	Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood, 2009, 114, 2837-2845.	0.6	140
108	Interaction of the globular domain of human C1q with Salmonella typhimurium lipopolysaccharide. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 1271-1276.	1.1	40

#	Article	IF	Citations
109	Antibodies Use Heme as a Cofactor to Extend Their Pathogen Elimination Activity and to Acquire New Effector Functions. Journal of Biological Chemistry, 2007, 282, 26696-26706.	1.6	81
110	C1q and its growing family. Immunobiology, 2007, 212, 253-266.	0.8	174
111	Complement C1qâ€target proteins recognition is inhibited by electric moment effectors. Journal of Molecular Recognition, 2007, 20, 405-415.	1.1	29
112	Iron Ions and Haeme Modulate the Binding Properties of Complement Subcomponent C1q and of Immunoglobulins. Scandinavian Journal of Immunology, 2007, 65, 230-239.	1.3	32
113	Interaction of C1q with IgG1, C-reactive Protein and Pentraxin 3:Â Mutational Studies Using Recombinant Globular Head Modules of Human C1q A, B, and C Chainsâ€. Biochemistry, 2006, 45, 4093-4104.	1.2	126
114	Existence of Different but Overlapping IgG- and IgM-Binding Sites on the Globular Domain of Human C1qâ€. Biochemistry, 2006, 45, 9979-9988.	1.2	45
115	Contribution of the C1q Polypeptide Chains in the Recognition of CRP. Biotechnology and Biotechnological Equipment, 2005, 19, 122-125.	0.5	0
116	Role of Ca2+in the Electrostatic Stability and the Functional Activity of the Globular Domain of Human C1qâ€. Biochemistry, 2005, 44, 14097-14109.	1.2	46
117	Mutational Analyses of the Recombinant Globular Regions of Human C1q A, B, and C Chains Suggest an Essential Role for Arginine and Histidine Residues in the C1q-IgG Interaction. Journal of Immunology, 2004, 172, 4351-4358.	0.4	72
118	Registration of the Interaction Between C1q Human Complement Derivatives and Immunoglobulins by Elisaâ€"Role of the Solid Phase. Biotechnology and Biotechnological Equipment, 2004, 18, 116-120.	0.5	0